



Now Proven to Deactivate, Decontaminate and Clean (DDC) Surface Exposures of Hazardous Drugs (HDs)



- **USP800** section entitled “DEACTIVATING, DECONTAMINATING, CLEANING, AND DISINFECTING” states:
 - All areas where hazardous drugs (HDs) are handled and all reusable equipment and devices must be deactivated, decontaminated, and cleaned (DDC).
 - DDC agents selected must be appropriate for the type of HD contaminant(s), location, and surface materials.
 - Agents used for DDC should be applied through the use of wipes wetted with appropriate solution and not delivered by a spray bottle to avoid spreading HD residue.
 - USP clarified that it is at the facility’s discretion to determine whether a single agent or process can satisfy one or more of the DDC steps.
- **HDClean**
 - HDClean is a two-step wiping procedure that effectively removes hazardous drug surface contamination.
 - Previously shown to be highly effective at decontaminating and completely removing a wide range of HDs from surfaces (Cox et al. JOPP’15; Zamboni et al. JOPP’17)
 - ****Updated Study Results and Indications****
 - **R&D studies of doxorubicin at 400 and 5000 ng/mL**
 - **HDClean results in chemical conversion of doxorubicin to alternate form(s)**
 - **HDClean significantly inhibits cytotoxicity of doxorubicin against normal cells and cancer cells**
 - **Chemical Conversion + Inhibition of Cytotoxicity = Deactivation**
- **HDClean** is the only product proven to DDC surface exposures of HDs and thus directly matches USP800 recommendations.